Pranas Šerpytis, Sigita Glaveckaitė, Mindaugas Lizaitis
Aim of the study – to find risk factors for longer hospitalization and additional treatment for patients with vitamin K antagonist overdose and to describe how hospitalization length and treatment quantities change after bleeding occurs. Methods. Following information about patients with vitamin K antagonists (warfarin) overdose was analysed: bleeding risk factors, overdose outcomes, hospitalization length, bleeding treatment. Results. 116 (77,3%) patients with bleeding and 48 (43,5%) without bleeding needed additional treatment for bleeding and/or following complications. (p<0,001). Patients with bleeding event needed more red blood cell units (p<0,001), fresh frozen plasma units (p<0,001), vitamin K (p=0,03). These differences are even bigger in group with major bleeding event (p<0,001). Previously diagnosed anaemia is a risk factor for additional treatment need during hospitalization (p<0,001). Average hospitalization length was longer for patients with anaemia (p=0,05), thrombocytopenia (p=0,05) or liver disease history (p=0,04), hospitalization length was significantly longer for patients with bleeding event (p=0,003), 11,8±8,7 days and 9,1±4,6 days respectively. The average hospitalization length for patients with haemorrhagic stroke was 23,3±18,2 days. Conclusions. Vitamin K antagonists overdose requires additional treatment and longer hospitalization: average hospitalization length is 3 days longer after bleeding occurs, and red blood cell units consumption has grown 10 times over five years.
Keyword(s): n K antagonists; warfarin overdose; hospitalization length; bleeding treatment.
Full Text: PDF